Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 6/2014

01-06-2014 | Original article

Role of brachytherapy in the treatment of cancers of the anal canal

Long-term follow-up and multivariate analysis of a large monocentric retrospective series

Authors: Laëtitia Lestrade, MD, Berardino De Bari, MD, Pascal Pommier, MD, PhD, Xavier Montbarbon, MD, Emilie Lavergne, Jean-Michel Ardiet, MD, Christian Carrie, MD

Published in: Strahlentherapie und Onkologie | Issue 6/2014

Login to get access

Abstract

Background and purpose

There are few data on long-term clinical results and tolerance of brachytherapy in anal canal cancer. We present one of the largest retrospective analyses of anal canal cancers treated with external beam radiotherapy with/without (±) chemotherapy followed by a brachytherapy boost.

Materials and methods

We performed a retrospective analysis of clinical results in terms of efficacy and toxicity. The impact of different clinical and therapeutic variables on these outcomes was studied.

Results

From May 1992 to December 2009, 209 patients received brachytherapy after external beam radiotherapy ± chemotherapy. Of these patients, 163 were stage II or stage IIIA (UICC 2002) and 58 were N1-3. According to age, ECOG performance status (PS), and comorbidities, patients received either radiotherapy alone (58/209) or radiochemotherapy (151/209). The median follow-up was 72.8 months. The 5- and 10-year local control rates were 78.6 and 73.9 %, respectively. Globally, severe acute and late G3–4 reactions (NCI-CTC scale v. 4.0) occurred in 11.2 and 6.3 % of patients, respectively. Univariate analysis showed the statistical impact of the pelvic treatment volume (p = 0.046) and of the total dose (p = 0.02) on the risk of severe acute and late toxicities, respectively. Only six patients required permanent colostomy because of severe late anorectal toxicities.

Conclusion

After a long follow-up time, brachytherapy showed an acceptable toxicity profile and high local control rates in patients with anal canal cancer.
Literature
1.
Williams M, Swampillai A, Osborne M et al Mount Vernon Colorectal Cancer Network (2013) Squamous cell carcinoma antigen: a potentially useful prognostic marker in squamous cell carcinoma of the anal canal and margin. Cancer 119:2391–2398
2.
No authors listed (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 348:1049–1054
3.
Bartelink H, Roelofsen F, Eschwege F et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 15:2040–2049PubMed
4.
Flam M, John M, Pajak TF et al (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14:2527–2539PubMed
5.
Ferrigno R, Nakamura RA, Dos Santos Novaes PE et al (2005) Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys 61:1136–1142PubMedCrossRef
6.
Huang K, Haas-Kogan D, Weinberg V et al (2007) Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol 13:895–900PubMed
7.
8.
Gerbaulet A, Pötter R, Mazeron JJ et al (2002) The GEC ESTRO Handbook of Brachytherapy (ISBN 90–804532–6). Bruxelles, pp. 505–514. (The Authors and ESTRO)
9.
Papillon J, Montbarbon JF, Gerard JP et al (1989) Interstitial curietherapy in the conservative treatment of anal and rectal cancers. Int J Radiat Oncol Biol Phys 17:1161–1169PubMedCrossRef
10.
Chapet O, Gerard JP, Riche B et al (2005) Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys 63:1316–1324PubMedCrossRef
11.
Tournier-Rangeard L, Peiffert D, Lafond C et al (2007) Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation. Cancer Radiother 11:169–177PubMedCrossRef
12.
Sobin LH, Gospodarowicz MK, Wittekind Ch (Eds) (2009) TNM classification of malignant tumors, 7th edn. Wiley-Blackwell, Oxford . (ISBN 978–1–4443–3241–4)
13.
14.
Womack NR, Morrison JF, Williams NS (1988) Prospective study of the effects of postanal repair in neurogenic faecal incontinence. Br J Surg 75:48–52PubMedCrossRef
15.
De Bari B, Bosset JF, Gérard JP et al (2012) Evidences in multidisciplinary management of rectal cancer. Cancer Radiother 16:711–720PubMedCrossRef
16.
Aggarwal A, Gayadeen S, Robinson D et al (2012) Clinical target volumes in anal cancer: calculating what dose was likely to have been delivered in the UK ACT II trial protocol. Radiother Oncol 103:341–346
17.
Nieder C (2013) Concurrent radiochemotherapy with 5-FU/mitomycin remains standard treatment for anal carcinoma. Long-term results of the phase III RTOG 98–11 trial. Strahlenther Onkol 189:512–513PubMedCrossRef
18.
Zilli T, Schick U, Ozsahin M et al (2012) Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy? Radiother Oncol 102:62–67
19.
Lestrade L, De Bari B, Montbarbon X et al (2013) Radiochemotherapy and brachytherapy could be the standard treatment of anal canal cancer in elderly patients? A retrospective single centre analysis. Med Oncol 30:402PubMedCrossRef
20.
De Bari B, Lestrade L, Chekrine T et al (2012) Should the treatment of anal carcinoma be adapted in the elderly? A retrospective analysis of acute toxicities in a French centre and a review of the literature (in French). Cancer Radiother 16:52–57
21.
Fraunholz I, Rabeneck D, Gerstein J et al (2011) Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? Radiother Oncol 98:99–104
22.
Fraass BA, Moran JM (2012) Quality, technology and outcomes: evolution and evaluation of new treatments and/or new technology. Semin Radiat Oncol 22:3–10. (Review)
23.
Valentini V, Bourhis J, Hollywood D (2012) ESTRO 2012 strategy meeting: vision for radiation oncology. Radiother Oncol 103:99–102
24.
Reddy S, Lee MS, Bonomi P et al (1994) Radiation therapy in the conservative treatment of carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 29:17–23CrossRef
25.
Peiffert D, Bey P, Pernot M et al (1997) Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications. Int J Radiat Oncol Biol Phys 37:313–324PubMedCrossRef
26.
Weber DC, Kurtz JM, Allal AS (2001) The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 50:675–680PubMedCrossRef
27.
Engineer R, Mallik S, Mahantshetty U et al (2010) Impact of radiation dose on locoregional control and survival on squamous cell carcinoma of anal canal. Radiother Oncol 95:283–287PubMedCrossRef
28.
Widder J, Kastenberger R, Fercher E et al (2008) Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol 87:367–375
29.
Touboul E, Schlienger M, Buffat L et al (1994) Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients. Cancer 73:1569–1579PubMedCrossRef
30.
Dewas CV, Maingon P, Dalban C et al (2012) Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer? Radiat Oncol 7:201PubMedCentralPubMedCrossRef
31.
Brooks CJ, Lee YK, Aitken K et al (2013) Organ-sparing intensity-modulated radiotherapy for anal cancer using the actii schedule: a comparison of conventional and intensity-modulated radiotherapy plans. Clin Oncol (R Coll Radiol) 25:155–61CrossRef
32.
Saarilahti K, Arponen P, Vaalavirta L et al (2008) The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 87:383–390PubMedCrossRef
Metadata
Title
Role of brachytherapy in the treatment of cancers of the anal canal
Long-term follow-up and multivariate analysis of a large monocentric retrospective series
Authors
Laëtitia Lestrade, MD
Berardino De Bari, MD
Pascal Pommier, MD, PhD
Xavier Montbarbon, MD
Emilie Lavergne
Jean-Michel Ardiet, MD
Christian Carrie, MD
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 6/2014
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-014-0628-y

Other articles of this Issue 6/2014

Strahlentherapie und Onkologie 6/2014 Go to the issue

Letter to the Editors

Is radiation an effective therapy in echinococcus multilocularis?

Literatur kommentiert

Vorsicht bei der hypofraktionierten dosiseskalierten Strahlentherapie beim nicht-kleinzelligen Bronchialkarzinom

Literatur kommentiert

Bevölkerungsbasierte Analyse von Komplikationen nach lokaler Therapie des Prostatakarzinoms

Erratum

Erratum to: The Erlangen Dose Optimization trial for low-dose radiotherapy of benign painful elbow syndrome

Original article

Robotic radiosurgery as an alternative to brachytherapy for cervical cancer patients

Erratum

Erratum to: The Erlangen Dose Optimization Trial for radiotherapy of benign painful shoulder syndrome